Cingulate, Inc. (CING)

NASDAQ: CING · IEX Real-Time Price · USD
1.19
+0.08 (7.73%)
At close: Oct 4, 2022 4:00 PM
1.15
-0.04 (-2.95%)
After-hours: Oct 4, 2022 6:44 PM EDT
7.73%
Market Cap 13.04M
Revenue (ttm) n/a
Net Income (ttm) -26.99M
Shares Out 11.00M
EPS (ttm) -2.16
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 21,386
Open 1.12
Previous Close 1.10
Day's Range 1.08 - 1.20
52-Week Range 0.94 - 5.15
Beta n/a
Analysts Buy
Price Target 8.67 (+631.6%)
Earnings Date Aug 11, 2022

About CING

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas. [Read more...]

Industry Biotechnology
IPO Date Dec 8, 2021
Employees 16
Stock Exchange NASDAQ
Ticker Symbol CING
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for CING stock is "Buy." The 12-month stock price forecast is 8.67, which is an increase of 631.65% from the latest price.

Price Target
$8.67
(631.65% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Cingulate Presents Data for Its Triple-Release Buspirone Product Candidate: CTx-2103

Data Demonstrated Ability of CTx-2103 to Deliver a Single Administration of Triple-Release Buspirone – Setting the Stage for Future Trials Employing Cingulate's Precision Timed Release™ (PTR™) Technology

2 weeks ago - GlobeNewsWire

Cingulate to Participate in Benzinga All Live Access Event

KANSAS CITY, Kan., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery pla...

1 month ago - GlobeNewsWire

Cingulate Inc. Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update

$5 Million of Non-Dilutive Financing Veteran Biotech Executive Appointed to Board

1 month ago - GlobeNewsWire

Kansas City Business Journal Names Cingulate's Louis G. Van Horn a 2022 Chief Financial Officer of the Year

KC Business Veteran, Two-Time Award Winner, Helped Lead Cingulate to 2021 IPO KC Business Veteran, Two-Time Award Winner, Helped Lead Cingulate to 2021 IPO

2 months ago - GlobeNewsWire

Cingulate Announces Completion of CTx-2103 Human Formulation Study for the Treatment of Anxiety Disorders

CTx-2103 (buspirone) is the Third Candidate Using Cingulate's Proprietary Precision Timed Release™ Drug Delivery Platform Technology for Once-daily Dosing Via Three Precise, Pre-defined Drug Releases CT...

3 months ago - GlobeNewsWire

Cingulate to Present at Diamond Equity Research 2022 Virtual Emerging Growth Invitational

KANSAS CITY, Kan., June 17, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery pla...

3 months ago - GlobeNewsWire

Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event

KANSAS CITY, Kan., June 02, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery pla...

4 months ago - GlobeNewsWire

Cingulate Announces Complete Enrollment in Human Formulation Study of CTx-2103 for the Treatment of Anxiety Disorders

Active Pharmaceutical Ingredient – Buspirone – One of the Most Widely Prescribed Agents in $5.5B U.S. Anxiety Market, Which Must be Taken Multiple Times Daily

4 months ago - GlobeNewsWire

Cingulate to Present at H.C. Wainwright Global Investment Conference

KANSAS CITY, Kan., May 18, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery plat...

4 months ago - GlobeNewsWire

Cingulate Inc. Reports First Quarter 2022 Results and Provides Clinical and Business Update

Announcement of First Dosage for Anxiety Candidate CTx-2103 to Extend the Application of the Precision Timed Release™ Platform (PTR™) Announcement of First Dosage for Anxiety Candidate CTx-2103 to Exten...

4 months ago - GlobeNewsWire

Cingulate Presents at NobleCon18

KANSAS CITY, Kan., April 26, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery pl...

5 months ago - GlobeNewsWire

Cingulate Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Clinical and Business Update

Completed Initial Public Offering, Raising Gross Proceeds of $25.0 Million

6 months ago - GlobeNewsWire

Cingulate to Present at Aegis Virtual Conference

KANSAS CITY, Kan., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery pla...

7 months ago - GlobeNewsWire

Cingulate Outlines Plan For Pivotal Attention Deficit/Hyperactivity Disorder Studies

Cingulate Inc CING plans to initiate Phase 3 studies for CTx-1301 for Attention Deficit/Hyperactivity Disorder (ADHD) in 2022. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

7 months ago - Benzinga

Cingulate Provides 2022 Clinical Plan for CTx-1301, an Investigational Medication for Attention Deficit/Hyperactivity...

Expedited Clinical Program Reduces Capital Requirements Expedited Clinical Program Reduces Capital Requirements

7 months ago - GlobeNewsWire

Cingulate Appoints Curt Medeiros and Gregg Givens to Board of Directors

Enhances Board's Expertise in Finance, Healthcare Technology, and Market Access Strategies Enhances Board's Expertise in Finance, Healthcare Technology, and Market Access Strategies

8 months ago - GlobeNewsWire

Aegis Capital Corp. acted as Lead Bookrunning Manager on a $25 Million Initial Public Offering of Common Stock for Ci...

NEW YORK, NY / ACCESSWIRE / December 10, 2021 / Aegis Capital Corp. acted as Lead Bookrunning Manager on a $25 Million Initial Public Offering of Common Stock for Cingulate Inc. (NASDAQ:CING). Cingulate...

9 months ago - Accesswire

Cingulate Inc. Announces Closing of Initial Public Offering

KANSAS CITY, Kan., Dec. 10, 2021 (GLOBE NEWSWIRE) -- Cingulate Inc. (“Cingulate” or the “Company”), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) d...

9 months ago - GlobeNewsWire

Cingulate Inc. Announces Pricing of $25.0 Million Initial Public Offering

KANSAS CITY, Kan., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Cingulate Inc. (“Cingulate” or the “Company”), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) d...

9 months ago - GlobeNewsWire